Poolbeg Pharma (LON:POLB) Trading Down 12.7% – What’s Next?

Poolbeg Pharma PLC (LON:POLB) traded down 12.7% during mid-day trading on Thursday . The company traded as low as GBX 7.50 and last traded at GBX 7.90. Approximately 8,713,230 shares traded hands during trading, an increase of 332% from the average session volume of 2,017,350 shares. The stock had previously closed at GBX 9.05.

Wall Street Analyst Weigh In

Separately, Shore Capital Group reiterated a “house stock” rating on shares of Poolbeg Pharma in a research note on Thursday.

Poolbeg Pharma Stock Down 12.7%

The stock has a 50-day simple moving average of GBX 7.94 and a 200-day simple moving average of GBX 6.35. The firm has a market capitalization of £60.31 million, a PE ratio of -8.40 and a beta of 1.83.

About Poolbeg Pharma

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.